Article thumbnail

The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes

By Vandana S. Raman, Kimberly J. Mason, Luisa M. Rodriguez, Krishnavathana Hassan, Xiaoying Yu, Lisa Bomgaars and Rubina A. Heptulla
Topics: Original Research
Publisher: American Diabetes Association
OAI identifier: oai:pubmedcentral.nih.gov:2875441
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1988). associated with intensive therapyintheDiabetesControlandComplications Trial.
  2. (1998). Effect of intensive blood-glucose control withmetforminoncomplicationsinoverweight patients with type 2
  3. (2006). Enhancing the action of incretin hormones: a new whey forward? Endocrinology
  4. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.
  5. (2008). GLP-1: physiological effects and potential therapeutic applications. Diabetes Obes Metab
  6. (2004). Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept
  7. SaadMF.Feasibilityofautomatinginsulin delivery for the treatment of type 1 diabetes.
  8. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
  9. (2006). The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet
  10. (2005). The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes. Diabetes
  11. The role of prandial pramlintide in the treatment of adolescents withtype1diabetes.PediatrRes2007;62:
  12. treatment and cardiovascular disease in patients with type 1 diabetes.
  13. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential beneļ¬t of replacing amylin, a second beta-cell hormone. Diabetes Technol Ther 2002;4: